苯磺酸氨氯地平联合阿托伐他汀钙治疗老年高血压伴血脂异常的临床研究  

Clinical trial of amlodipine combined with atorvastatin calcium in the treatment of elderly hypertension with dyslipidemia

作　　者：陈慧敏[1] 许逸飞[2] 

机构地区：[1]浙江省中医院预防保健科,杭州310006 [2]浙江省中医院心内科,杭州310006

出　　处：《中国临床药理学杂志》2016年第12期1072-1074,共3页The Chinese Journal of Clinical Pharmacology

基　　金：浙江省中医药科技计划基金资助项目(2009A004)

摘　　要：目的观察苯磺酸氨氯地平联合阿托伐他汀钙治疗老年高血压伴血脂异常的临床疗效及安全性。方法将78例老年高血压伴血脂异常患者随机分为对照组39例与试验组39例。对照组予以晨起口服苯磺酸氨氯地平5 mg,qd;试验组在对照组的基础上,予以睡前口服阿托伐他汀钙10 mg。2组患者一个周期均为28 d,共治疗2个周期。比较2组患者的临床疗效、治疗前后的收缩压(SBP)、舒张压(DBP)、血清总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平以及不良反应发生情况。结果治疗后,试验组的总有效率为94.87%显著高于对照组的79.49%(P<0.05)。2组患者治疗后的SBP、DBP、TC、TG、LDL-C水平较治疗前显著降低,且试验组治疗后上述指标水平显著低于对照组(P<0.05)。试验组治疗后的HDL-C水平较治疗前显著升高(P<0.05),而对照组治疗前后的HDL-C水平比较差异无统计学意义(P>0.05),且试验组治疗后的HDL-C水平显著高于对照组(P<0.05)。对照组和试验组的不良反应发生率分别为7.69%和12.82%,差异无统计学意义(P>0.05)。结论苯磺酸氨氯地平联合阿托伐他汀钙治疗老年高血压伴血脂异常的临床疗效显著,且不增加不良反应的发生率。Objective To evaluate the efficacy and safety of amlodipine combined with atorvastatin calcium in the treatment of elderly hypertension with dyslipidemia. Methods Seventy - eight patients of elderly hy- pertension with dyslipidemia were divided into control group （n = 39） and treatment group （n = 39）. Control group was given amlodipine 5 rag, qd. Treatment group was treated with atorvastatin calcium 10 mg, oral with per night, on the basis of the control group. Two groups were with treated for 2 cycles with 28 d per cycle. The clinical efficacy, systolic blood pressure （SBP）, diastolic blood pressure （DBP）, total cholesterol（ TC）, triglyceride （ TG）, high - density lipoprotein cholesterol （ HDL - C ）, low -density lipoprotein cholesterol（ LDL- C） , and incidence of adverse drug reactions were compared in two groups. Results After treatment, the total effective rate in treatment group was significantly higher than that in control group（94. 87% vs 79. 49%, P 〈0. 05）. The levels of SBP, DBP, TC, TG, LDL - C after treatment were significantly lower than those before treatment （P 〈 0. 05 ）, and the those indexes in treatment group after treatment were significantly lower than those of control group （P 〈 0. 05 ）. The level of serum HDL - C in treatment group was higher than that in control group, with statistically significant difference （ P 〈 0. 05 ）. The incidences of adverse drug reactions in treatment and control group were 12. 82%, 7.69% , respectively, without statistically significant different（ P 〉 0. 05 ）. Conclusion Amlodipine combined with atorvastatin calcium have a definitive clinical efficacy for has a definitive clinical efficacy for the treatment of elderly hypertension with dyslipidemia, without increasing the incidence of adverse drug reactions.

关 键 词：苯磺酸氨氯地平 阿托伐他汀钙 老年高血压伴血脂异常 安全性 

分 类 号：R972.6[医药卫生—药品]